Clinical Trials Logo

Filter by:
NCT ID: NCT00259766 Completed - Asthma Clinical Trials

SHARE - Symbicort and Health Economics in a Real Life Evaluation

Start date: April 2004
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare health-related costs and asthma control in ordinary clinical practice during 12 months for Symbicort® given as a low maintenance dose plus as needed compared to a free combination of Pulmicortâ and Oxis® plus Bricanyl® as needed, and Symbicort fixed dosing plus Bricanyl as needed in asthmatic patients not adequately controlled on inhaled glucocorticosteroids alone.

NCT ID: NCT00258453 Completed - Clinical trials for Brain and Central Nervous System Tumors

Observation of Young Patients Who Are Undergoing Surgery for Craniopharyngioma

Start date: May 2001
Phase: N/A
Study type: Interventional

RATIONALE: Collecting information on how craniopharyngioma is diagnosed and treated may help doctors predict a patient's response to treatment and help plan the best treatment. It may also help identify the intermediate- and long-term effects of treatment. PURPOSE: This clinical trial is collecting information on diagnosis, treatment, and quality of life of young patients who are undergoing surgery for craniopharyngioma.

NCT ID: NCT00257205 Completed - Melanoma Clinical Trials

CP-675,206 Versus Either Dacarbazine Or Temozolomide In Patients Without Prior Therapy

Start date: March 2006
Phase: Phase 3
Study type: Interventional

This is a Phase 3, multi-national, open-label, 2-arm randomized study in patients with surgically incurable metastatic melanoma who have received no prior chemotherapy, or biochemotherapy for the treatment of metastatic disease. The primary objective of this trial is to compare overall survival for patients with advanced melanoma who are randomized to receive CP-675,206 with that of patients who are randomized to receive either dacarbazine or temozolomide (investigator choice)

NCT ID: NCT00256919 Completed - Clinical trials for Arthritis, Rheumatoid

Single Dose Study Of GW856553 On A Protein That Is An Indicator For Rheumatoid Arthritis (RA)

Start date: November 2005
Phase: Phase 2
Study type: Interventional

This study is designed to compare a range of doses of GW856553 versus placebo on the biomarkers associated with rheumatoid arthritis

NCT ID: NCT00256893 Completed - Clinical trials for Fibromyalgia Syndrome, Primary

Fibromyalgia Study In Adults

Start date: November 2004
Phase: Phase 2
Study type: Interventional

A study to investigate ropinirole for treatment of the symptoms of fibromyalgia and in particular the widespread pain associated with this condition. A total 160 subjects (80 per treatment arm) are being recruited from approximately 25 centres in 9 European countries. Male and female subjects greater than 18 years of age with a diagnosis of primary fibromyalgia, as defined by the American College of Rheumatology (ACR) criteria, are eligible for study entry. Subjects will receive either ropinirole (1-24mg) or placebo, depending upon a statistically defined allocation to treatment. The primary endpoint is improvement in pain score by 12 weeks of treatment. An 11 point numerical rating scale for the assessment of the subject's pain is being collected on a daily diary. In addition, the overall improvement in quality of life for the subject will be assessed by means of a number of subject-completed questionnaires during the treatment period. Safety of the treatment regimen will be assessed throughout the study.

NCT ID: NCT00256750 Completed - Clinical trials for Kidney Transplantation

Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression (BENEFIT)

BENEFIT
Start date: March 2005
Phase: Phase 3
Study type: Interventional

The purpose of this study is to learn if Belatacept can provide protection from organ rejection following kidney transplantation while avoiding some of the toxic effects of standard immunosuppressive medications such as kidney damage. Effects on kidney function and patient survival as well as drug safety will also be studied.

NCT ID: NCT00256737 Completed - GERD Clinical Trials

Sopran - Omeprazole Treatment Versus Surgery

Start date: January 1998
Phase: Phase 3
Study type: Interventional

The purpose of this study is to study gastritis, GI symptoms during long term omeprazole treatment

NCT ID: NCT00256698 Completed - Breast Cancer Clinical Trials

Anastrozole Monotherapy Versus Maximal Oestrogen Blockade With Anastrozole and Fulvestrant Combination Therapy

FACT
Start date: January 2004
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine the efficacy of anastrozole monotherapy versus maximal oestrogen blockade with combinated therapy of fulvestrant and anastrozole compared with in treatment of hormone receptor positive women with first relapse of breast cancer.

NCT ID: NCT00256126 Completed - Clinical trials for Growth Hormone Deficiency

Predictive Markers in Growth Hormone Deficiency (GHD) and Turner Syndrome (TS) Children Treated With SAIZEN®

Start date: May 31, 2005
Phase: Phase 4
Study type: Interventional

The study aims at identifying the predictive markers after one month of Saizen therapy in Growth Hormone Deficiency (GHD) and Turner Syndrome children.

NCT ID: NCT00255606 Completed - Prostate Cancer Clinical Trials

Docetaxel and Prednisone in Treating Patients With Hormone-Refractory Metastatic Prostate Cancer

Start date: August 2005
Phase: Phase 3
Study type: Interventional

RATIONALE: Drugs used in chemotherapy, such as docetaxel and prednisone, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. It is not yet known which schedule of docetaxel and prednisone is more effective in treating prostate cancer. PURPOSE: This randomized phase III trial is studying two different schedules of docetaxel and prednisone to compare how well they work in treating patients with metastatic prostate cancer.